Educational reference. Research use only.
Tirzepatide: Mechanism, Research, and Regulatory Status
Tirzepatide (LY3298176) is a synthetic 39-amino-acid dual agonist of the GLP-1 and GIP receptors, CAS 2023788-19-2, molecular weight 4813.47 Da. Tirzepatide has been studied in 4 published Phase 3 human trials summarized here: SURPASS-1, SURPASS-2, SURMOUNT-1 and SURMOUNT-2. Tirzepatide is FDA-approved as Mounjaro and Zepbound; research-grade material is for laboratory use only.
Listed in the Veridian catalog as GLP-2 Tirz.
Last reviewed 2026-09-29
What is Tirzepatide?
Tirzepatide key facts
Tirzepatide, coded LY3298176 and listed in the Veridian catalog as GLP-2 Tirz, is a 39-amino-acid peptide built on the native GIP sequence, with CAS number 2023788-19-2 and a molecular weight of 4813.47 Da. A C18 fatty diacid attached through a linker binds albumin and extends the plasma half-life of tirzepatide to about five days. Tirzepatide activates both the glucagon-like peptide-1 receptor and the glucose-dependent insulinotropic polypeptide receptor. In SURPASS-2 (Frías and colleagues, New England Journal of Medicine, 2021, n=1,879), tirzepatide lowered HbA1c by 2.46 percentage points versus 1.86 with semaglutide over 40 weeks. In SURMOUNT-1 (Jastreboff and colleagues, New England Journal of Medicine, 2022, n=2,539), the top arm recorded a mean 22.5% body-weight reduction versus 2.4% with placebo over 72 weeks. SURMOUNT-2 (Garvey and colleagues, The Lancet, 2023, n=938) studied adults with obesity and type 2 diabetes. Tirzepatide is FDA-approved as Mounjaro (2022) and Zepbound (2023); research-grade tirzepatide is not the approved drug product and is supplied for laboratory research use only.
How does Tirzepatide work?
Tirzepatide (LY3298176) is a synthetic dual agonist peptide that activates both the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). Structurally, it is a 39-amino acid peptide based on the native GIP sequence, with modifications that let it also activate GLP-1R. A C18 fatty diacid chain is attached through a linker so the peptide binds albumin, the most abundant blood protein.
That binding extends plasma half-life to approximately 5 days. GLP-1R agonism reduces appetite through hypothalamic and brainstem satiety pathways, slows gastric emptying, and augments glucose-stimulated insulin release from pancreatic beta cells while suppressing glucagon. GIPR agonism complements this by further potentiating insulin secretion in a glucose-dependent manner.
It may also modulate adipocyte lipid metabolism, reduce glucagon secretion, and enhance the appetite-suppressing (anorectic) effects of GLP-1R signaling through central GIPR circuits in the hypothalamus and area postrema. Tirzepatide received FDA approval for type 2 diabetes (Mounjaro, May 2022) and obesity (Zepbound, November 2023), making it the first approved dual GLP-1/GIP agonist.
One molecule, two receptors
GLP-2 Tirz is a dual agonist: it activates two incretin receptors rather than one. Tap a receptor to see what each contributes.
GLP-1R
Glucagon-like peptide-1 receptor
- Reduces appetite through satiety signalling in the brain
- Slows gastric emptying
- Increases insulin release when glucose is elevated
What has research on Tirzepatide found?
What published peer-reviewed research and preclinical studies have established about Tirzepatide:
- 01FDA-approved dual GLP-1/GIP receptor agonist (Mounjaro for T2D, 2022; Zepbound for obesity, 2023)
- 02SURMOUNT-1 (NEJM 2022, n=2,539, 72 weeks): the highest-exposure arm achieved −22.5% mean body weight vs −2.4% placebo. That was the largest weight reduction observed in an obesity drug trial at time of publication
- 03SURPASS-2 (NEJM 2021): the highest-exposure tirzepatide arm reduced HbA1c by −2.46% vs −1.86% for the semaglutide comparator in T2D patients (p<0.001)
- 04SURPASS-CVOT: cardiovascular outcomes trial ongoing; interim mortality and MACE data pending
- 05SURMOUNT-2 (T2D+obesity, 72 weeks): highest-exposure arm −15.7% weight vs −3.3% placebo
- 06SURMOUNT-3 and SURMOUNT-4 explore maintenance therapy and intensive lifestyle plus tirzepatide combinations
- 07SURPASS-NASH: Phase 3 trial evaluating tirzepatide in metabolic dysfunction-associated steatohepatitis (MASH)
Which studies have examined Tirzepatide?
SURMOUNT-1
Phase 3 RCT · 2022Highest-exposure arm: −22.5% body weight vs −2.4% placebo; 63% achieved ≥20% weight loss; lower-exposure arms −15.0% and −19.5%
SURPASS-2
Phase 3 RCT (active comparator) · 2021Highest-exposure tirzepatide arm: HbA1c −2.46% vs semaglutide −1.86% (p<0.001); body weight −12.4 kg vs −6.2 kg
SURPASS-1
Phase 3 RCT · 2021Highest-exposure arm: HbA1c −2.11% vs −0.01% placebo; 92% of participants achieved HbA1c <7%; fasting glucose −53 mg/dL
SURMOUNT-2 (T2D + obesity)
Phase 3 RCT · 2023Highest-exposure arm: −15.7% body weight vs −3.3% placebo; HbA1c −2.1% vs −0.4%; 66% achieved ≥10% weight loss
Frequently asked questions about Tirzepatide
How does tirzepatide compare to semaglutide (Ozempic/Wegovy)?+
SURPASS-2 (head-to-head RCT) showed the highest-exposure tirzepatide arm produced significantly greater HbA1c reduction (−2.46% vs −1.86%) and weight loss (−12.4 kg vs −6.2 kg) than the semaglutide comparator in T2D. Indirect comparisons across separate obesity trials suggest ~22.5% weight loss with tirzepatide vs ~17.4% with semaglutide, though direct head-to-head data in obesity are limited.
What are the contraindications relevant to research protocols?+
Models with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2) are standard exclusions based on FDA labeling. In rodent studies, GLP-1R agonists showed dose-dependent C-cell hyperplasia; the human relevance remains under investigation. Pancreatitis history is also an exclusion in clinical trials.
Is tirzepatide being studied for conditions beyond T2D and obesity?+
Yes. Active research areas include: heart failure with preserved ejection fraction (SUMMIT trial, Phase 3, positive results 2023); MASH/NAFLD (SURPASS-NASH); sleep apnea (SURMOUNT-OSA); chronic kidney disease; and polycystic ovary syndrome (PCOS). The SUMMIT trial showed significant improvement in 6-minute walk distance and KCCQ symptoms.
What is the half-life and pharmacokinetic profile?+
Tirzepatide has a ~5-day elimination half-life due to albumin binding via its C18 fatty diacid chain. Peak plasma concentration (Tmax) is reported at roughly 8–72 hours. Mild to moderate renal or hepatic impairment did not materially change exposure in the published pharmacokinetic work, although volume depletion is a recognized risk.
What is the legal status for research procurement?+
Tirzepatide is FDA-approved (Schedule uncontrolled) and available as a licensed pharmaceutical (Mounjaro, Zepbound). For research, institutional purchase from licensed pharmaceutical suppliers is standard. WADA classifies tirzepatide as a prohibited substance under S2. Compounded tirzepatide was widely available during the shortage period (2022–2024) but FDA has moved to restrict unapproved compounding.
Can tirzepatide cause muscle loss?+
Clinical trials show that roughly 40% of total weight lost with GLP-1-class agents, including tirzepatide, is lean mass. That is higher than the ~25–30% lean mass fraction lost through lifestyle intervention alone. SURMOUNT-1 body composition sub-studies documented fat-free mass reduction. Ongoing research is evaluating whether resistance training or anabolic agents preserve lean mass during pharmacological weight loss.
References & sources
Every citation below was resolved against its primary source before publication. Each PMID was checked against its PubMed record and each DOI through doi.org. Follow any link to read the paper at the publisher rather than taking our summary on trust.
- [1]Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022. PMID: 35658024 DOI: 10.1056/NEJMoa2206038
- [2]Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021. PMID: 34170647 DOI: 10.1056/NEJMoa2107519
- [3]Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet. 2021. PMID: 34186022 DOI: 10.1016/S0140-6736(21)01324-6
- [4]Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet. 2023. PMID: 37385275 DOI: 10.1016/S0140-6736(23)01200-X
- [5]Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023. PMID: 37952131 DOI: 10.1056/NEJMoa2307563
- [6]Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovascular Diabetology. 2022. PMID: 36050763 DOI: 10.1186/s12933-022-01604-7
- [7]Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature Medicine. 2023. PMID: 37840095 DOI: 10.1038/s41591-023-02597-w
Where this data comes from
- Citations & trial data: PubMed (NCBI, U.S. National Library of Medicine), Crossref and ClinicalTrials.gov.
- Chemical identity: PubChem and UniProt. Where sources conflicted, the disputed value is omitted rather than guessed.
- Regulatory status: U.S. FDA publications and, where applicable, the WADA Prohibited List. Compounding status changes often, so check FDA directly before relying on it.
- Purity, form and storage are handling and supplier conventions, not literature-derived values. Confirm against the lot-specific certificate of analysis. General handling is covered in the storage and stability guide.
Content last reviewed 2026-09-29. Compiled by Veridian Research from the primary literature. This page is an educational reference for laboratory researchers. It is not medical advice, and it describes no human use.
Is Tirzepatide approved for human use?
Tirzepatide is FDA-approved as Mounjaro® (type 2 diabetes, 2022) and Zepbound® (obesity, 2023). Use outside approved indications is investigational. WADA classifies tirzepatide as a prohibited substance under S2. Compounded tirzepatide from 503B outsourcing facilities was permitted during the drug shortage period; FDA has announced plans to restrict this as branded supply normalizes. For research purposes outside approved indications only.
Research-use-only material
Specifications and certificate of analysis
Tirzepatide is stocked as a research reagent. Analytical documentation, covering identity, purity and the lot-specific certificate of analysis, is published in the certificate library.